Skip Navigation

ASH News Daily / By Julie Kanter, MD

December 09 2013

Dr. Julie Kanter contributed to ASH News Daily during The American Society of Hematology (ASH) 55th Annual Meeting. Her article covered advances in treatment of sickle cell disease, including hematopoietic stem cell transplantation (HSCT) and current trials using unrelated donors, umbilical cord blood and haploidentical donors. Dr. Jeffrey Chell, CEO of Be The Match, is quoted in the article, expressing Be The Match’s commitment to supporting patients during the transplant process so that “financial and social barriers don’t prevent curative options.”